Biography
Marty Tenenbaum is a renowned computer scientist, Internet entrepreneur and cancer warrior. He is the Founder and Chairman of Cancer Commons, a non-profit network of physicians, scientists, and patients that Newsweek dubbed the “LinkedIn of Cancer.” He began his career in AI, leading elite research groups at SRI International and Schlumberger Ltd. Later, as an Internet commerce pioneer, he founded or co-founded five successful startups. Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, a former Director of Commerce One, the Public Library of Science (PLoS) and Patients Like Me, and a former consulting professor of Computer Science at Stanford. He currently serves as a Director of CommerceNet and Efficient Finance. Dr. Tenenbaum holds B.S. and M.S. degrees in Electrical Engineering from MIT, and a Ph.D. from Stanford, and has received numerous awards for his contributions to AI and his work as a patient advocate.

Biography
Erika joined Cancer Commons in 2016 as one of Silicon Valley’s only nonprofits focused on serving cancer patients globally through aligning incentives around the patient to produce better outcomes. In Erika’s role as Executive Director, she is responsible for overseeing the growth of Cancer Commons and operations. Today, Cancer Commons is one of the leading cancer knowledge networks. The network brings together the world’s top cancer experts, advisors, pharma, oncologists and super-patient groups all focused on delivering the best treatment option to each person with cancer, at scale globally. Before joining Cancer Commons, Erika took time to start a family here in the Bay Area after working abroad in Europe as a strategic management consultant in the Strategic Information Technology Practice in AT Kearney. She then moved into a leadership role with Wunderman, a global digital agency and CRM company, headquartered in New York with 200 offices in 70 markets. Erika earned her bachelor’s degree from the University of California San Diego where she double majored in Political Science and Economics and received her International MBA from SDA Bocconi in Milan, Italy, one of the most prestigious business schools in the world. Erika is fluent in three languages, a mother of three, and is committed to helping the lives of others while making an impact on the organizations she serves.

Biography
Mika has more than 20 years of commercial strategy and leadership experience in life sciences, with a focus on novel technologies. Over the last 10 years Mika has concentrated on evidence-based medicine and tools to transform healthcare and clinical development. Before joining xCures he was the Chief Commercial Officer of Doctor Evidence, LLC. Prior to Doctor Evidence he was the General Manager of Clinical Development Services at diaDexus, SVP of Client and Market Development at Evidera, VP of Sales and Marketing at Archimedes, and held sales management and sales operations roles at Quintiles, Invitrogen and Tripos.

Biography
Dr. Kinsey’s primary clinical responsibilities are in Gastrointestinal Medical Oncology. He initially set out on the path to become a physician-scientist by conducting undergraduate research at Bucknell University studying Osteosarcoma. During his Medical Scientist Training Program training at the University of Rochester he was mentored by Hartmut K. Land PhD investigating the role of PLAC8 in autophagy and gastrointestinal malignancies. The major emphasis of his recent research has been to discover new therapeutic opportunities for pancreatic cancer with the combination of MAP Kinase signaling inhibition and autophagy inhibition. This has resulted in two clinical trials targeting MEK/ERK and autophagy in RAS mutated gastrointestinal malignancies of which Dr. Kinsey is the Primary Investigator.

Biography
Dr. Carla Grandori is an internationally recognized physician-scientist who pioneered new technologies to develop the next generation of cancer therapeutics tailored to each individual’s tumor. Dr. Grandori’s entrepreneurial experience and network drove the growth of SEngine Precision Medicine. She has recruited a world-class team including a Nobel Prize Laureate and a Pulitzer Prize-winning oncologist. Dr. Grandori raised seed and Series A funding for SEngine Precision Medicine to enable CLIA certification for SEngine’s high-throughput test, the PARIS® assay, guiding cancer treatment options. This funding enables the development of therapies targeting previously undruggable oncogenes including MYC, KRAS and TP53. The oncology startup is accelerating drug discovery and functional precision medicine to transform cancer care. Dr. Grandori received her MD from the University of Rome and Ph.D. from the Rockefeller University in New York. The majority of her scientific career was at the Fred Hutchinson Cancer Research Center in Seattle.

Biography
Dr. Snyder is a Neuro-Oncologist at the Hermelin Brain Tumor Center of Henry Ford Health System dedicated to improving access to innovative clinical trials and comprehensive multidisciplinary care. Dr. Snyder specializes in the care of people with cancer or tumors involving the nervous system. He is a leader in the brain, spine, and molecular tumor boards for the health system. Dr. Snyder is active in all phases of clinical trials as well as translational research, including: epigenomics, radiomics, and clinical data curation to drive real-world-evidence and precision medicine initiatives. Dr. Snyder has been recognized for his work addressing access to care barriers for the neuro-oncology community through virtual connectivity and a disease navigation virtual tumor board platform. First and foremost, Dr. Snyder is a committed advocate for his patients, their families, and the neuro-oncology community, driving patient-centric innovation and progress.

Biography
Harvey J. Cohen is the Deborah E. Addicott – John A. Kriewall and Betsy A. Haehl Family Professor in Pediatrics at Stanford University School of Medicine, and the Katie and Paul Dougherty Medical Director of Palliative Care Lucile Packard Children’s Hospital at Stanford. Dr. Cohen was previously Chairman of the Department of Pediatrics at Stanford University, where he was the Arline and Pete Harman Professor, and the Adalyn Jay Chief of Staff at Lucile Packard Children’s Hospital. Dr. Cohen obtained both his MD and Ph.D. from Duke University and was a pediatric intern at the Children’s Hospital in Boston. He completed a fellowship in Pediatric Hematology/Oncology at Children’s Hospital and the Dana Farber Cancer Institute and was named assistant then associate professor of pediatrics at Harvard Medical School.